Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
4
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
N/ANon-phased studies
4(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A4 (100.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completednot_applicable

Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.

NCT05635604
completednot_applicable

The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

NCT04960657
completednot_applicable

The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients

NCT02364453
completednot_applicable

PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow

NCT00380263

Clinical Trials (4)

Showing 4 of 4 trials
NCT05635604Not Applicable

Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.

Completed
NCT04960657Not Applicable

The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

Completed
NCT02364453Not Applicable

The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients

Completed
NCT00380263Not Applicable

PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4